A Joint Model for the Kinetics of CTC Count and PSA Concentration During Treatment in Metastatic Castration-Resistant Prostate Cancer*

Assessment of treatment efficacy in metastatic castration‐resistant prostate cancer (mCRPC) is limited by frequent nonmeasurable bone metastases. The count of circulating tumor cells (CTCs) is a promising surrogate marker that may replace the widely used prostate‐specific antigen (PSA). The purpose of this study was to quantify the dynamic relationships between the longitudinal kinetics of these markers during treatment in patients with mCRPC. Data from 223 patients with mCRPC treated by chemotherapy and/or hormonotherapy were analyzed for up to 6 months of treatment. A semimechanistic model was built, combining the following several pharmacometric advanced features: (1) Kinetic‐Pharmacodynamic (K‐PD) compartments for treatments (chemotherapy and hormonotherapy); (2) a latent variable linking both marker kinetics; (3) modeling of CTC kinetics with a cell lifespan model; and (4) a negative binomial distribution for the CTC random sampling. Linked with survival, this model would potentially be useful for predicting treatment efficacy during drug development or for therapeutic adjustment in treated patients.

[1]  G. Murphy,et al.  Purification of a human prostate specific antigen. , 1979, Investigative urology.

[2]  Y. Ko,et al.  PSA-based treatment response criteria in castration-resistant prostate cancer: promises and limitations. , 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[3]  E N Jonsson,et al.  Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. , 1999, Computer methods and programs in biomedicine.

[4]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[5]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[6]  K. Pienta,et al.  Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer , 2008, Clinical Cancer Research.

[7]  J. P. Perez Ruixo,et al.  Lifespan based indirect response models , 2012, Journal of Pharmacokinetics and Pharmacodynamics.

[8]  Leon W M M Terstappen,et al.  Statistical considerations for enumeration of circulating tumor cells , 2007, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[9]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[10]  C. Parker,et al.  Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized double-blind, placebo-controlled phase III study of abiraterone acetat , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[12]  W. Jusko,et al.  Population Cell Life Span Models for Effects of Drugs Following Indirect Mechanisms of Action , 2005, Journal of Pharmacokinetics and Pharmacodynamics.

[13]  Larry Norton,et al.  Tumor Self-Seeding by Circulating Cancer Cells , 2009, Cell.

[14]  Mehmet Toner,et al.  Isolation and Characterization of Circulating Tumor Cells from Patients with Localized and Metastatic Prostate Cancer , 2010, Science Translational Medicine.

[15]  Mats O. Karlsson,et al.  Performance in population models for count data, part I: maximum likelihood approximations , 2009, Journal of Pharmacokinetics and Pharmacodynamics.

[16]  Tanja Fehm,et al.  Circulating Tumor Cells in Patients with Breast Cancer Dormancy , 2004, Clinical Cancer Research.

[17]  L. Collette.  Re: Design and endpoints of clinical trials in patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, European urology.

[18]  L. Terstappen,et al.  Interpretation of changes in circulating tumor cell counts. , 2012, Translational oncology.

[19]  Varun Garg,et al.  Comparison of four basic models of indirect pharmacodynamic responses , 1993, Journal of Pharmacokinetics and Biopharmaceutics.

[20]  Ss Beal,et al.  NONMEM User’s Guides. (1989–2009) , 2009 .

[21]  Michael Morse,et al.  Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  I. Thompson,et al.  Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  C. Tangen,et al.  Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. , 2006, Journal of the National Cancer Institute.

[24]  R. Gieschke,et al.  Modelling Response Time Profiles in the Absence of Drug Concentrations: Definition and Performance Evaluation of the K–PD Model , 2007, Journal of Pharmacokinetics and Pharmacodynamics.

[25]  Stuart L. Beal,et al.  Ways to Fit a PK Model with Some Data Below the Quantification Limit , 2001, Journal of Pharmacokinetics and Pharmacodynamics.

[26]  Peter L. Bonate,et al.  Modeling tumor growth kinetics after treatment with pazopanib or placebo in patients with renal cell carcinoma , 2013, Cancer Chemotherapy and Pharmacology.

[27]  Xiaoyu Jia,et al.  Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. , 2009, The Lancet. Oncology.

[28]  E. Niclas Jonsson,et al.  Perl-speaks-NONMEM (PsN) - a Perl module for NONMEM related programming , 2004, Comput. Methods Programs Biomed..

[29]  M Tod,et al.  A critical review of the analytical approaches for circulating tumor biomarker kinetics during treatment. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  Susan Halabi,et al.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Alison Stopeck,et al.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.

[32]  H. Moch,et al.  Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. , 2000, Human pathology.

[33]  G. Klee,et al.  How sensitive is a prostate-specific antigen measurement? How sensitive does it need to be? , 2004, Archives of pathology & laboratory medicine.

[34]  V. Bobek,et al.  Essentials of circulating tumor cells for clinical research and practice. , 2013, Critical reviews in oncology/hematology.

[35]  L. Sheiner,et al.  Evaluating Pharmacokinetic/Pharmacodynamic Models Using the Posterior Predictive Check , 2001, Journal of Pharmacokinetics and Pharmacodynamics.

[36]  Jonathan W. Uhr,et al.  Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases , 2004, Clinical Cancer Research.

[37]  L E Friberg,et al.  A Review of Mixed-Effects Models of Tumor Growth and Effects of Anticancer Drug Treatment Used in Population Analysis , 2014, CPT: pharmacometrics & systems pharmacology.